Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral
crenolanib versus oral placebo in combination with best supportive care in subjects with
advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120
subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching
placebo orally (PO) 3 times daily (TID) in combination with best supportive care.